Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Phase 4, Open-label, Non-randomized, Prospective Study of OZURDEX® in the Treatment of Diabetic Macular Oedema - The AUSSIEDEX Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New South Wales
-
Hurtsville, New South Wales, Australia, 2220
- Retina and Macula Specialists,Hurstville
-
Liverpool, New South Wales, Australia, 2170
- Retina Associates
-
Miranda, New South Wales, Australia, 2228
- Retina and Macula Specialists, Miranda
-
Mona Vale, New South Wales, Australia, 2103
- Eye Doctors Mona Vale
-
Parramatta, New South Wales, Australia, 2150
- Marsden Eye Clinic
-
Strathfield, New South Wales, Australia, 2135
- Retina & Vitreous Centre Strathfield
-
Strathfield, New South Wales, Australia, 2135
- Strathfield Retina
-
Sydney, New South Wales, Australia, 2000
- Retina & Vitreous Centre City
-
Sydney, New South Wales, Australia, 2000
- Sydney Eye and Retina Clinic
-
Sydney, New South Wales, Australia, 2000
- Sydney Eye Hospital/Macular Diseases Centre
-
Westmead, New South Wales, Australia, 2145
- Sydney West Retina
-
-
Queensland
-
Brisbane, Queensland, Australia, 4000
- Terrace Eye Centre
-
Caboolture, Queensland, Australia, 4510
- Caboolture Eye Surgery
-
Redcliffe, Queensland, Australia, 4020
- Peninsula Eye Hospital
-
South Brisbane, Queensland, Australia, 4101
- The Qld Eye Institute
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Adelaide Eye & Retina Centre
-
Adelaide, South Australia, Australia, 5000
- Department of Opthalmology, Royal Adelaide Hospital
-
-
Tasmania
-
Hobart, Tasmania, Australia, 5000
- Hobart Eye Surgeons
-
Launceston, Tasmania, Australia, 7249
- Tasmanian Eye Institute
-
-
Victoria
-
Essendon, Victoria, Australia, 3040
- Essendon Retina
-
Fitzroy, Victoria, Australia, 3065
- Victoria Parade Eye Consultants
-
Footscry, Victoria, Australia, 3011
- Vision Eye Institute
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Lions Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pseudophakic or phakic and scheduled for a cataract operation
- Macular oedema due to DME
Exclusion Criteria:
- Previous Ozurdex® treatment
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Ozurdex® (dexamethasone intravitreal implant)
Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
|
Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean change in Best Corrected Visual Acuity (BCVA) from baseline
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
Mean change in Central Retinal Thickness (CRT) from baseline
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients with a BCVA improvement of 15 letters or more
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
Percentage of patients with a BCVA improvement of 10 letters or more
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
BCVA average mean from baseline in area under the curve (AUC) analysis
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
Number of Intraocular Pressure (IOP)-lowering treatments used to control IOP increase
Time Frame: 12 Months
|
12 Months
|
|
Mean BCVA at each injection number
Time Frame: 12 Months
|
12 Months
|
|
Mean change from baseline in BCVA at each injection number
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
Mean change in BCVA across all the study injection numbers
Time Frame: Baseline, 12 Months
|
Baseline, 12 Months
|
|
Percentage of patients with BCVA improvement
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
Percentage of BCVA losers
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
|
Percentage of patients improving to 20/40 or better
Time Frame: Month 12
|
Month 12
|
|
Mean number of Ozurdex injections
Time Frame: 12 Months
|
12 Months
|
|
Mean interval between Ozurdex® injections
Time Frame: 12 Months
|
12 Months
|
|
Change from baseline in central subfield retinal thickness by Optical Coherence Tomography (OCT) before each follow-up injection number
Time Frame: Baseline, Month 12
|
Baseline, Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Dr. George Labib, Allergan
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Macular Edema
- Edema
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
Other Study ID Numbers
- CMO-AP-EYE-0438
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.